2
Views
2
CrossRef citations to date
0
Altmetric
Anatomical Pathology

Cyclin‐dependent kinase (cdk6) and p16 in pancreatic endocrine neoplasms

Pages 566-570 | Received 18 Aug 2003, Accepted 28 May 2004, Published online: 06 Jul 2009

References

  • Rosenthal ET, Hurst T, Ruderman JV. Selective translation of mRNA controls: The comparison of protein synthesis during early development of the surf clam. Cell 1980; 20: 489–94.
  • Johnson DG, Walker CL. Cyclins and cell cycle check-points. Annu Rev Pharmacol Toxicol 1999; 39: 295–312.
  • Tsihlias JJ, Kapusta L, Slingerland J. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med 1999; 50: 401–32.
  • Tsihlias J, Kapusta LR, DeBooer G, Morava-Protzner I, Zbieranowski I, Bhattacharya N. Loss of cyclin-dependent kinase inhibitor p27 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998; 58: 542–8.
  • Sherr CJ. Cancer cell cycles. Science 1996; 274: 1672–7.
  • Sherr CJ. G1 phase progression: cycling on cue. Cell 1994; 79: 551–5.
  • Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase cdk4. Genes Dev 1993; 7: 331–42.
  • Tomita T. New markers for pancreatic islets and islet cell tumors. Pathol Int 2002; 52: 425–32.
  • Cattoretti G, Becker MH, Key G, et al. Monoclonal antibodies against recombinant parts of Ki-67 antigen detect proliferating cells in microwave-processed formalin-fixed, paraffin sections. J Pathol 1992; 168: 357–63.
  • Tomita T, Iwata K. Gelatinases and inhibitors of gelatinases in pancreatic islets and islet cell tumors. Mod Pathol 1997; 10: 47–54.
  • Tomita T. Metallothionein in pancreatic endocrine neoplasms. Mod Pathol 2000; 13: 389–95.
  • Tomita T. Immunocytotochemical localization of prohormone con-vertase 1/3 and 2 in pancreatic islets and islet cell tumors. Pancreas 2001; 23: 172–6.
  • Tomita T. Amylin in human pancreatic islets. Pathology 2003; 35: 34–6.
  • Hoog A, Hu W, Abdel-Halim SM, Falkmer S. Ultrastructural localization of insulin-like growth factor-2 to the secretary granules of insulin cells. Ultrastruct Pathol 1997; 21: 457–66.
  • Alcorta DA, Xiong Y, Phelps D, Hannon C, Bearch D, Barrett C. Involvement of the cyclin-dependent kinase inhibitor p16 in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93: 13742–7.
  • Reithdorf L, Reithdorf S, Lee KR, Cviko A, Loning T, Crum CP. Human papillomavirus expression of p16 and early endocervical glandular neoplasm. Hum Pathol 2002; 33: 899–904.
  • Baba Y, Tsukuda M, Mochimatsu I, Fukukawa S, Kagata H, Satake S. Reduced expression of p16 and p27 proteins in nasopharygeal carcinoma. Cancer Detect Prey 2001; 25: 414–9.
  • Kouvaraki M, Gorgoulis VS, Rassidakis GZ. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas. Cancer 2002; 94: 2454–65.
  • Vis AN, Noordzij MA, Fitoz K, Wildhagen MF, Schroder FH, van der Kwast TH. Prognostic value of cell cycle proteins p27kip 1 and MIB-1, and the cell adhesion protein CD 44s in surgically treated patients with prostate cancer. J Urol 2000; 164: 2156–61.
  • Shibata H, Matubara 0, Wakiyama H, Tanaka S. The role of cyclin-dependent kinase inhibitor p27 in squamous cell carcinoma of the esophagus. Pathol Res Pract 2001; 197: 157–64.
  • Thomas GU, Szugetu K, Murphy M, Dracetta G, Pagano M, Loda M. Down-regulation of p27 is associated with development of colorectal adenocarcinoma metastasis. Am J Pathol 1998; 153: 681–7.
  • Hashimoto K, Nio Y, Sumi S, et al. Correlation between TGF-a beta 1 and p21(WAF1/CIP1) expression and prognosis in respectable invasive ductal carcinoma of the pancreas. Pancreas 2001; 22: 341–7.
  • Tanmapfel A, Grund D, Katalinic A, et al. Decreased expression of p27 protein is associated with advanced tumor stage in hepatocelluar carcinoma. Int J Cancer 2000; 89: 350–5.
  • Huang LW, Chao SL, Hwang JL, Chou YY. Down-regulation of p27 is associated with malignant transformation and aggressive phenotype of cervical neoplasms. Gynecol Oncol 2002; 85: 524–8.
  • Watanabe J, Sato H, Kanai T, et al. Paradoxical expression of cell cycle inhibitor p27 in endometrioid adenocarcinoma of the uterine corpus-Correlation with proliferation and clinicopathological para-meters. Br J Cancer 2002; 87: 81–5.
  • Shigemasa K, Shiroyama Y, Sawasaki T, et al. Underexpression of cyclin-dependent kinase inhibitor p27 is associated with poor prognosis in serous ovarian carcinomas. Int J Oncol 2001; 18: 953–8.
  • Erickson LA, Yousef OM, Jin L, Lohse CM, Pankratz VS, Lloyd RV. p27kipl expression distinguishes papillary hyperplasia in Grave's disease from papillary thyroid carcinoma. Mod Pathol 2000; 13: 1014–9.
  • Nakabayashi H, Sunada H, Hara M. Immmunohistochemical analysis of cell cycle-regulated protein, apoptosis and proliferation in pituitary adenomas. J Histochem Cytochem 2001; 49: 1193–4.
  • Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT, Oldfield EH. Heterogeneity of subcellular localization of p53 pattern in human glioblastomas. Cancer Res 1994; 54: 1–5.
  • Lilja L, Yang SN, Webb DL, Juntti-Berggren I, Bergren PO, Bark C. Cyclin-dependent kinase 5 promotes insulin exocytosis. J Biol Chem 2001; 276: 34199–205.
  • Marzo N, Mora C, Fabregat ME, et al. Pancreatic islets from cyclin-dependent kinase 4/R24C (cdk4) knockin mice have significantly increased beta cell mass and are physiologically functional, indicating that cdk4 is a potential target for pancreatic beta cell mass regeneration in Type 1 diabetes. Diabetologia 2004; 47: 686–94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.